ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
NMPA approves Novartis's Cosentyx for psoriasis patients
April 03, 2019Cosentyx is the first biologic approved in China that specifically inhibits interleukin-17A (IL-17A), a cornerstone cytokine involved in the inflammation of psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) -
Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin
July 05, 2018Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1].
Pharma Sources Insight January 2025
